Synagis (palivizumab) / SOBI, AbbVie, AstraZeneca  >>  Phase 2
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Synagis (palivizumab) / SOBI
NCT00240929: A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)

Completed
2
150
US
MEDI-493, Synagis
MedImmune LLC
-Unhealthy Children With a History of Prematurity
 
04/03
NCT00316264: Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Completed
2
260
RoW
Motavizumab, palivizumab, Palivizumab, motavizumab, Motavizumab
MedImmune LLC
Respiratory Syncytial Virus Infections, Chronic Lung Disease and <= 24 Months of Age or, Premature With Gestational Age <=35 Weeks and <=6 Months of Age
02/07
02/07
NCT00538785 / 2007-002070-61: A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Completed
2
1236
US, Canada, Europe, RoW
Motavizumab, Medi-524, Palivizumab, Synagis
MedImmune LLC
Congenital Heart Disease
06/08
06/08
2005-001671-35: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children with Hemodynamically Significant Congenital Heart Disease

Completed
2
1400
Europe, RoW, Canada, US
Numax, Palivizumab, MEDI-524, MEDI-493, Solution for injection, Synagis
MedImmune, Inc., MedImmune, LLC, , MedImmune, LLC
Serious respiratory syncytial virus (RSV) disease in children with hemodynamically significant congential heart disease (CHD)., Serious respiratory syncytial virus (RSV) disease in children with hemodynamically significant congential heart disease (CHD, Diseases [C] - Respiratory Tract Diseases [C08]
 
05/06
2020-004137-21: Nasal administration of palivizumab in an RSV human challenge model

Completed
2
34
Europe
Commercial Synagis, Nasal drops
University Medical Center Utrecht, University Medical Center Utrecht
respiratory syncytial virus infection, respiratory syncytial virus infection, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT00113490: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Completed
1/2
136
RoW
motavizumab (MEDI-524), motavizumab, Rezield, palivizumab 15 mg/kg, synagis
MedImmune LLC
Motavizumab Administration for a Second Season for RSV Prophylaxis
02/06
02/06
2018-002742-37: Nasal administration of palivizumab to prevent respiratory syncytial virus infection Narsyn: Nasale toediening van palivizumab om RS-virus infectie te voorkomen

Completed
1/2
408
Europe
Commercial Synagis, Nasal drops
University Medical Center Utrecht, University Medical Center Utrecht
respiratory syncytial virus infection, respiratory syncytial virus infection, Diseases [C] - Respiratory Tract Diseases [C08]
 
 

Download Options